Shots:
- NetraMark and Worldwide Clinical Trials have entered into a global agreement to utilize NetraMark’s NetraAI platform to advance clinical trial design
- As per the deal, NetraAI will initially support P-II neuroscience & oncology trials, plus select P-III studies conducted by Worldwide, with broader access extended to Worldwide’s sponsors across all therapeutic areas & trial phases
- Collaboration will leverage Worldwide’s expertise & NetraMark AI platform to accelerate development, improve patient stratification, reduce PBO variability, enhance trial power, & deliver regulatory-aligned insights from complex datasets for advancing clinical trial success
Ref: Prnewswire | Image: NetraMark & Worldwide
Related News:- Suvoda Launches AI assistant Sofia to Streamline Clinical Trial Management
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
